Novel therapeutic targets in rheumatoid arthritis.
Rheumatoid arthritis (RA) is an autoimmune disease that leads to inflammation and destruction of synovial joints. Despite the broad spectrum of antirheumatic drugs, this heterogeneous disease is still not well controlled in up to 30% of patients. Here, we discuss two pathways that are regarded as interesting novel therapeutic targets in the field of rheumatology: the Janus kinase (JAK) pathway and the T helper-17 (Th17) pathway [including interleukin (IL)-17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF)]. We also review the therapy potential of biologicals and small-molecule inhibitors blocking these pathways. Advances in combination therapy in addition to progress in biomarker screening will help us to further achieve effective and personalized healthcare for patients with RA.
Radboud University Medical Center, Experimental Rheumatology, Nijmegen, The Netherlands. Electronic address: Marije.Koenders@radboudumc.nl.
Marije I
MI
Koenders
Radboud University Medical Center, Experimental Rheumatology, Nijmegen, The Netherlands.
Wim B
WB
van den Berg
D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000378:metabolism*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism*; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D016503:Drug Delivery Systems / Q000639:trends*; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D058504:Th17 Cells / Q000187:drug effects / Q000378:metabolism
D018501:Antirheumatic Agents; D016207:Cytokines; D053612:Janus Kinases
IL-17; JAK; Th17; rheumatoid arthritis; therapeutic targets